Jose Villar

Jose Villar

Auto-generated profile, based on publicly available information

Jose Villar

Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
FBFernando C. Barros
Fernando C. Barros
RGRobert B. Gunier
Robert B. Gunier
ARAlbertina Rego
Albertina Rego
LSLoic SENTILHES
Loic SENTILHES
SRStephen Rauch
Stephen Rauch
JVJose Villar
Jose Villar
In early 2023, when Omicron was the variant of concern, we showed that vaccinating pregnant women decreased the risk of severe COVID-19 related complications, and maternal morbidity and mortality. To analyze the impact of COVID-19 during pregnancy on newborns and the effects of maternal COVID-19 vaccination on neonatal outcomes, when Omicron was the variant of concern. INTERCOVID-2022 is a large, prospective, observational study, conducted in 40 hospitals across 18 countries, from November 27, 2021 (the day after the World Health Organization declared Omicron the variant of concern) to June 30, 2022, to assess the effect of COVID-19 in pregnancy on maternal and neonatal outcomes, as well as vaccine effectiveness (VE). Women diagnosed with laboratory-confirmed COVID-19 in pregnancy were compared with two 'non-diagnosed', unmatched women recruited concomitantly and consecutively in pregnancy or at delivery. Mother/newborn dyads were followed until hospital discharge. Primary outcomes were a neonatal positive test for COVID-19, severe neonatal morbidity index (SNMI), severe perinatal morbidity and mortality index (SPMMI), preterm birth, neonatal death, referral to neonatal intensive care unit (NICU), and diseases during the neonatal period. VE was estimated adjusted by maternal risk profile. We enrolled 4707 neonates born to 1577 (33.5%) mothers diagnosed with COVID-19 and 3130 (66.5%) non-diagnosed mothers. Amongst diagnosed mothers, 642 (40.7%) were not vaccinated, 147 (9.3%) were partially vaccinated, 551 (34.9%) were completely vaccinated, and 237 (15.0%) also had a booster vaccine. Neonates of booster-vaccinated mothers had less than half (RR=0.46; 95%CI=0.23, 0.91) the risk of being diagnosed with COVID-19 compared to those of unvaccinated mothers; they also had the lowest rates of preterm birth, medically-indicated preterm birth, respiratory distress syndrome and number of days in NICU. Newborns of unvaccinated mothers had double the risk of neonatal death (RR=2.06; 95% CI=1.06, 4.00) compared to those of non-diagnosed mothers. Vaccination was not associated with any congenital malformations. Although all vaccines provided protection against neonatal test positivity, newborns of booster-vaccinated mothers had the significantly highest VE (64%; 95% CI=10-86%); VE was not as high for mRNA vaccines only. VE against moderate/severe neonatal outcomes was much lower: 13% in the booster-vaccinated group (all vaccines), and 25% and 28% in the completely and booster-vaccinated groups, respectively (mRNA vaccines only). Vaccines were fairly effective in protecting neonates when given to pregnant women 100 days (14 weeks) or less before birth; thereafter, the risk increased and was much higher after 200 days (29 weeks).. Finally, none of the neonatal practices studied, including skin-to-skin contact and direct breastfeeding, increased the risk of infecting newborns. When Omicron was the variant of concern, newborns of unvaccinated mothers had an increased risk of neonatal death. Neonates of vaccinated mothers had a decreased risk of preterm birth and adverse neonatal outcomes. As the protective effect of COVID-19 vaccination decreases with time, to ensure that newborns are maximally protected against COVID-19 mothers should receive a vaccine or booster dose no more than 14 weeks before the expected date of delivery.

1 July 2016 in Obstetrical & Gynecological Survey
Verified
Journal Article
Closed access
Leila Cheikh IsmailLeila Cheikh Ismail
Leila Cheikh Ismail
DBDeborah C. Bishop
Deborah C. Bishop
RPRuyan Pang
Ruyan Pang
EOEric O. Ohuma
Eric O. Ohuma
GKGilberto Kac
Gilberto Kac
JVJosé Villar
José Villar
(Abstracted from BMJ 2016;352:i555) Associations between insufficient or excessive gestational weight gain (GWG) and short- and long-term maternal and child health outcomes have been well described. Insufficient weight gain has been linked with increased risks of low birth weight, small for gestational age, and preterm birth,while excessive gain has been associated with large for gestational age, gestational diabetes, preterm birth, caesarean section, infant mortality, postpartum weight retention, and childhood obesity.

16 September 2025
Verified
Thesis
Open access
JVJosmary Antuanette Salas Villar
Josmary Antuanette Salas Villar
Introducción: Este estudio busca ampliar el conocimiento sobre los factores de riesgo obstétricos de la disfunción del piso pélvico (DPP), una condición postparto que debilita el tejido pélvico y provoca problemas urinarios y sexuales, afectando la calidad de vida de las mujeres. Objetivo: Determinar los factores de riesgo obstétricos para disfunción de piso pélvico hasta el primer año de seguimiento del parto vaginal en mujeres primíparas con desgarro perineal atendidas en el Hospital Nacional Docente Madre Niño San Bartolomé (HND-SB) 2025-2026. Materiales y Métodos: Este será observacional, analítico y prospectivo, con diseño de casos y controles. La muestra estará compuesta por 240 mujeres primíparas con parto vaginal y desgarro perineal que firmen el consentimiento informado. De estas, 80 presentarán DPP y 160 no. Se empleará un muestreo probabilístico sistemático y los datos se recolectarán mediante una ficha estructurada, la cual será codificada para garantizar la confidencialidad. La variable independiente será los factores de riesgo obstétricos, y la variable dependiente será la DPP. El análisis de los datos se realizará utilizando el software SPSS v27, con análisis descriptivo, pruebas de Chi-cuadrado, Odds Ratio (OR) y Odds Ratio Ajustado (ORa) en un modelo multivariado.

1 January 2003
Verified
Book Chapter
Closed access
EAE. Abalos
E. Abalos
GCG. Carroli
G. Carroli
JCJ. Campodónico
J. Campodónico
JVJ. Villar
J. Villar